以 IL-17A 为靶点,控制黑色素瘤免疫疗法引起的毒性。

IF 20.1 1区 医学 Q1 ONCOLOGY
Kai Huang
{"title":"以 IL-17A 为靶点,控制黑色素瘤免疫疗法引起的毒性。","authors":"Kai Huang","doi":"10.1002/cac2.12628","DOIUrl":null,"url":null,"abstract":"<p>The landscape of cancer treatment has been dramatically transformed by the advent of immune checkpoint inhibitors (ICIs), particularly in the management of advanced melanoma. However, despite their revolutionary success, the use of ICIs is often complicated by immune-related adverse events (irAEs), which can range from mild symptoms to severe, life-threatening conditions. Understanding the underlying mechanisms of these toxicities is crucial to enhancing the safety and effectiveness of immunotherapy [<span>1</span>].</p><p>In a recent study published in <i>Nature Cancer</i>, Dimitriou <i>et al.</i> [<span>2</span>] provide novel insights into the immunological processes driving irAEs in melanoma patients treated with ICIs. The researchers identified a significant increase in interleukin-17A (IL-17A) expressing CD4<sup>+</sup> T cells at the onset of irAEs, pointing to a type III immune response as a key factor in these adverse events. This discovery not only deepens our understanding of irAEs but also suggests a potential therapeutic target for mitigating these toxicities without compromising the antitumor efficacy of ICIs.</p><p>What sets these findings apart is their contribution to a broader understanding of the mechanisms behind ICIs’ AEs compared to primary autoimmune diseases. While irAEs share certain immune mechanisms with autoimmune diseases, such as rheumatoid arthritis or psoriasis, the immunological context of ICIs is distinct because of the pharmacological disruption of immune checkpoints [<span>3</span>]. The study highlights the difference between irAEs and primary autoimmune disease by showing that IL-17A expressing CD4<sup>+</sup> T cells are particularly implicated in ICI-induced toxicity, which is not a prominent feature of many primary autoimmune conditions.</p><p>The study utilized a comprehensive approach, including proteomic analyses, multiplex cytokine and chemokine assays, and flow cytometry, to examine the immune profiles of melanoma patients undergoing ICI therapy. A critical finding was the consistent upregulation of IL-17A, along with other type I and III cytokines, at the onset of irAEs. These results were corroborated by the observation that IL-17A expressing CD4<sup>+</sup> T cells were significantly elevated in patients experiencing irAEs compared to those who did not.</p><p>Importantly, the authors provided proof-of-principle evidence for the therapeutic potential of targeting IL-17A in managing irAEs. In a small cohort of patients with severe, corticosteroid-refractory irAEs, treatment with the anti-IL-17A monoclonal antibody secukinumab led to a resolution of symptoms. Secukinumab, primarily used in the treatment of psoriasis, where IL-17A plays a well-established pathogenic role, offers a novel therapeutic option for managing irAEs [<span>4</span>]. Its efficacy in these patients not only underscores the importance of IL-17A in both conditions but also suggests that treatment strategies from autoimmune diseases can be successfully repurposed for irAEs in cancer immunotherapy. This outcome suggests that IL-17A blockade could be a viable strategy for controlling irAEs, offering a new avenue for improving the safety profile of ICIs in melanoma treatment.</p><p>These findings are particularly relevant given the expanding use of ICIs across various cancers. The ability to identify patients at risk for severe irAEs through biomarkers like IL-17A could enable more personalized treatment approaches. Moreover, the successful use of secukinumab in this context opens the door to broader clinical trials aimed at validating IL-17A as a therapeutic target, potentially leading to the development of new protocols for managing irAEs.</p><p>The implications of this study extend beyond melanoma. The mechanisms of irAEs are likely to be similar across different cancers treated with ICIs, suggesting that these findings could have broader applicability. As such, researchers and clinicians should consider exploring the role of IL-17A and type III immune responses in other oncological contexts, with the goal of developing more effective and personalized immunotherapy strategies.</p><p>In conclusion, this study marks a significant advancement in the field of cancer immunotherapy. By identifying IL-17A expressing CD4<sup>+</sup> T cells as a central player in irAE development, the study not only enhances our understanding of these toxicities but also provides a promising new target for therapeutic intervention. As the use of ICIs continues to grow, these findings offer a path forward for improving patient outcomes by balancing the benefits of immunotherapy with the need to manage its associated risks effectively.</p><p>Kai Huang drafted and revised the manuscript.</p><p>The author declares no conflict of interest.</p><p>Not applicable.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"45 1","pages":"56-57"},"PeriodicalIF":20.1000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758441/pdf/","citationCount":"0","resultStr":"{\"title\":\"Targeting IL-17A to manage immunotherapy-induced toxicity in melanoma\",\"authors\":\"Kai Huang\",\"doi\":\"10.1002/cac2.12628\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The landscape of cancer treatment has been dramatically transformed by the advent of immune checkpoint inhibitors (ICIs), particularly in the management of advanced melanoma. However, despite their revolutionary success, the use of ICIs is often complicated by immune-related adverse events (irAEs), which can range from mild symptoms to severe, life-threatening conditions. Understanding the underlying mechanisms of these toxicities is crucial to enhancing the safety and effectiveness of immunotherapy [<span>1</span>].</p><p>In a recent study published in <i>Nature Cancer</i>, Dimitriou <i>et al.</i> [<span>2</span>] provide novel insights into the immunological processes driving irAEs in melanoma patients treated with ICIs. The researchers identified a significant increase in interleukin-17A (IL-17A) expressing CD4<sup>+</sup> T cells at the onset of irAEs, pointing to a type III immune response as a key factor in these adverse events. This discovery not only deepens our understanding of irAEs but also suggests a potential therapeutic target for mitigating these toxicities without compromising the antitumor efficacy of ICIs.</p><p>What sets these findings apart is their contribution to a broader understanding of the mechanisms behind ICIs’ AEs compared to primary autoimmune diseases. While irAEs share certain immune mechanisms with autoimmune diseases, such as rheumatoid arthritis or psoriasis, the immunological context of ICIs is distinct because of the pharmacological disruption of immune checkpoints [<span>3</span>]. The study highlights the difference between irAEs and primary autoimmune disease by showing that IL-17A expressing CD4<sup>+</sup> T cells are particularly implicated in ICI-induced toxicity, which is not a prominent feature of many primary autoimmune conditions.</p><p>The study utilized a comprehensive approach, including proteomic analyses, multiplex cytokine and chemokine assays, and flow cytometry, to examine the immune profiles of melanoma patients undergoing ICI therapy. A critical finding was the consistent upregulation of IL-17A, along with other type I and III cytokines, at the onset of irAEs. These results were corroborated by the observation that IL-17A expressing CD4<sup>+</sup> T cells were significantly elevated in patients experiencing irAEs compared to those who did not.</p><p>Importantly, the authors provided proof-of-principle evidence for the therapeutic potential of targeting IL-17A in managing irAEs. In a small cohort of patients with severe, corticosteroid-refractory irAEs, treatment with the anti-IL-17A monoclonal antibody secukinumab led to a resolution of symptoms. Secukinumab, primarily used in the treatment of psoriasis, where IL-17A plays a well-established pathogenic role, offers a novel therapeutic option for managing irAEs [<span>4</span>]. Its efficacy in these patients not only underscores the importance of IL-17A in both conditions but also suggests that treatment strategies from autoimmune diseases can be successfully repurposed for irAEs in cancer immunotherapy. This outcome suggests that IL-17A blockade could be a viable strategy for controlling irAEs, offering a new avenue for improving the safety profile of ICIs in melanoma treatment.</p><p>These findings are particularly relevant given the expanding use of ICIs across various cancers. The ability to identify patients at risk for severe irAEs through biomarkers like IL-17A could enable more personalized treatment approaches. Moreover, the successful use of secukinumab in this context opens the door to broader clinical trials aimed at validating IL-17A as a therapeutic target, potentially leading to the development of new protocols for managing irAEs.</p><p>The implications of this study extend beyond melanoma. The mechanisms of irAEs are likely to be similar across different cancers treated with ICIs, suggesting that these findings could have broader applicability. As such, researchers and clinicians should consider exploring the role of IL-17A and type III immune responses in other oncological contexts, with the goal of developing more effective and personalized immunotherapy strategies.</p><p>In conclusion, this study marks a significant advancement in the field of cancer immunotherapy. By identifying IL-17A expressing CD4<sup>+</sup> T cells as a central player in irAE development, the study not only enhances our understanding of these toxicities but also provides a promising new target for therapeutic intervention. As the use of ICIs continues to grow, these findings offer a path forward for improving patient outcomes by balancing the benefits of immunotherapy with the need to manage its associated risks effectively.</p><p>Kai Huang drafted and revised the manuscript.</p><p>The author declares no conflict of interest.</p><p>Not applicable.</p>\",\"PeriodicalId\":9495,\"journal\":{\"name\":\"Cancer Communications\",\"volume\":\"45 1\",\"pages\":\"56-57\"},\"PeriodicalIF\":20.1000,\"publicationDate\":\"2024-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758441/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Communications\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cac2.12628\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Communications","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cac2.12628","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

免疫检查点抑制剂(ICIs)的出现极大地改变了癌症治疗的前景,特别是在晚期黑色素瘤的治疗中。然而,尽管ici取得了革命性的成功,但它的使用往往会因免疫相关不良事件(irAEs)而复杂化,这些不良事件可能从轻微症状到严重的危及生命的疾病。了解这些毒性的潜在机制对于提高免疫疗法的安全性和有效性至关重要。在最近发表在《自然癌症》杂志上的一项研究中,Dimitriou等人提供了新的见解,了解了在接受ICIs治疗的黑色素瘤患者中驱动irae的免疫过程。研究人员发现,在irAEs发病时,表达CD4+ T细胞的白细胞介素- 17a (IL-17A)显著增加,这表明III型免疫反应是这些不良事件的关键因素。这一发现不仅加深了我们对irae的理解,而且还提出了一个潜在的治疗靶点,可以在不影响ICIs抗肿瘤功效的情况下减轻这些毒性。这些发现的不同之处在于,它们有助于更广泛地理解与原发性自身免疫性疾病相比,ICIs ae背后的机制。虽然irae与自身免疫性疾病(如类风湿关节炎或牛皮癣)具有某些相同的免疫机制,但ICIs的免疫学背景是不同的,因为免疫检查点bbb的药理学破坏。该研究强调了irae与原发性自身免疫性疾病之间的差异,表明表达CD4+ T细胞的IL-17A特别涉及ici诱导的毒性,而这并不是许多原发性自身免疫性疾病的突出特征。该研究采用了综合方法,包括蛋白质组学分析、多重细胞因子和趋化因子分析以及流式细胞术,来检查接受ICI治疗的黑色素瘤患者的免疫谱。一个关键的发现是IL-17A的持续上调,以及其他I型和III型细胞因子,在irAEs发病时。观察结果证实了这些结果,即与未经历irAEs的患者相比,经历irAEs的患者中表达CD4+ T细胞的IL-17A显着升高。重要的是,作者为靶向IL-17A治疗irAEs的治疗潜力提供了原则性证据。在一小部分严重的皮质类固醇难治性irAEs患者中,使用抗il - 17a单克隆抗体secukinumab治疗导致症状缓解。Secukinumab主要用于治疗银屑病,其中IL-17A发挥着公认的致病作用,为管理irAEs[4]提供了一种新的治疗选择。它在这些患者中的疗效不仅强调了IL-17A在这两种疾病中的重要性,而且还表明,自身免疫性疾病的治疗策略可以成功地在癌症免疫治疗中重新用于irae。这一结果表明,IL-17A阻断可能是一种控制irae的可行策略,为提高ICIs在黑色素瘤治疗中的安全性提供了新的途径。鉴于在各种癌症中扩大使用ICIs,这些发现尤其相关。通过IL-17A等生物标志物识别有严重irae风险的患者的能力可以实现更个性化的治疗方法。此外,在这种情况下,secukinumab的成功使用为更广泛的临床试验打开了大门,旨在验证IL-17A作为治疗靶点,可能导致管理irae的新方案的发展。这项研究的意义超出了黑色素瘤。在使用ICIs治疗的不同癌症中,irae的机制可能是相似的,这表明这些发现可能具有更广泛的适用性。因此,研究人员和临床医生应该考虑探索IL-17A和III型免疫反应在其他肿瘤环境中的作用,以开发更有效和个性化的免疫治疗策略。总之,这项研究标志着癌症免疫治疗领域的重大进展。通过确定IL-17A表达CD4+ T细胞在irAE发展中的核心作用,该研究不仅增强了我们对这些毒性的理解,而且为治疗干预提供了一个有希望的新靶点。随着ICIs使用的持续增长,这些发现为通过平衡免疫治疗的益处与有效管理相关风险的需要来改善患者预后提供了一条前进的道路。黄凯起草并修改了原稿。作者声明不存在利益冲突。不适用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Targeting IL-17A to manage immunotherapy-induced toxicity in melanoma

The landscape of cancer treatment has been dramatically transformed by the advent of immune checkpoint inhibitors (ICIs), particularly in the management of advanced melanoma. However, despite their revolutionary success, the use of ICIs is often complicated by immune-related adverse events (irAEs), which can range from mild symptoms to severe, life-threatening conditions. Understanding the underlying mechanisms of these toxicities is crucial to enhancing the safety and effectiveness of immunotherapy [1].

In a recent study published in Nature Cancer, Dimitriou et al. [2] provide novel insights into the immunological processes driving irAEs in melanoma patients treated with ICIs. The researchers identified a significant increase in interleukin-17A (IL-17A) expressing CD4+ T cells at the onset of irAEs, pointing to a type III immune response as a key factor in these adverse events. This discovery not only deepens our understanding of irAEs but also suggests a potential therapeutic target for mitigating these toxicities without compromising the antitumor efficacy of ICIs.

What sets these findings apart is their contribution to a broader understanding of the mechanisms behind ICIs’ AEs compared to primary autoimmune diseases. While irAEs share certain immune mechanisms with autoimmune diseases, such as rheumatoid arthritis or psoriasis, the immunological context of ICIs is distinct because of the pharmacological disruption of immune checkpoints [3]. The study highlights the difference between irAEs and primary autoimmune disease by showing that IL-17A expressing CD4+ T cells are particularly implicated in ICI-induced toxicity, which is not a prominent feature of many primary autoimmune conditions.

The study utilized a comprehensive approach, including proteomic analyses, multiplex cytokine and chemokine assays, and flow cytometry, to examine the immune profiles of melanoma patients undergoing ICI therapy. A critical finding was the consistent upregulation of IL-17A, along with other type I and III cytokines, at the onset of irAEs. These results were corroborated by the observation that IL-17A expressing CD4+ T cells were significantly elevated in patients experiencing irAEs compared to those who did not.

Importantly, the authors provided proof-of-principle evidence for the therapeutic potential of targeting IL-17A in managing irAEs. In a small cohort of patients with severe, corticosteroid-refractory irAEs, treatment with the anti-IL-17A monoclonal antibody secukinumab led to a resolution of symptoms. Secukinumab, primarily used in the treatment of psoriasis, where IL-17A plays a well-established pathogenic role, offers a novel therapeutic option for managing irAEs [4]. Its efficacy in these patients not only underscores the importance of IL-17A in both conditions but also suggests that treatment strategies from autoimmune diseases can be successfully repurposed for irAEs in cancer immunotherapy. This outcome suggests that IL-17A blockade could be a viable strategy for controlling irAEs, offering a new avenue for improving the safety profile of ICIs in melanoma treatment.

These findings are particularly relevant given the expanding use of ICIs across various cancers. The ability to identify patients at risk for severe irAEs through biomarkers like IL-17A could enable more personalized treatment approaches. Moreover, the successful use of secukinumab in this context opens the door to broader clinical trials aimed at validating IL-17A as a therapeutic target, potentially leading to the development of new protocols for managing irAEs.

The implications of this study extend beyond melanoma. The mechanisms of irAEs are likely to be similar across different cancers treated with ICIs, suggesting that these findings could have broader applicability. As such, researchers and clinicians should consider exploring the role of IL-17A and type III immune responses in other oncological contexts, with the goal of developing more effective and personalized immunotherapy strategies.

In conclusion, this study marks a significant advancement in the field of cancer immunotherapy. By identifying IL-17A expressing CD4+ T cells as a central player in irAE development, the study not only enhances our understanding of these toxicities but also provides a promising new target for therapeutic intervention. As the use of ICIs continues to grow, these findings offer a path forward for improving patient outcomes by balancing the benefits of immunotherapy with the need to manage its associated risks effectively.

Kai Huang drafted and revised the manuscript.

The author declares no conflict of interest.

Not applicable.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer Communications
Cancer Communications Biochemistry, Genetics and Molecular Biology-Cancer Research
CiteScore
25.50
自引率
4.30%
发文量
153
审稿时长
4 weeks
期刊介绍: Cancer Communications is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信